DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes

Kunal Kumar, Chalada Suebsuwong, Peng Wang, Adolfo Garcia-Ocana, Andrew F. Stewart, Robert J. Devita

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose control to prevent long-term diabetes complications. Unfortunately, current therapies have failed to achieve glycemic targets in the majority of people with diabetes. In this context, regeneration of functional insulin-producing human β-cells in people with diabetes through the use of DYRK1A inhibitor drugs has recently received special attention. Several small molecule DYRK1A inhibitors have been identified that induce human β-cell proliferation in vitro and in vivo. Furthermore, DYRK1A inhibitors have also been shown to synergize β-cell proliferation with other classes of drugs, such as TGFβ inhibitors and GLP-1 receptor agonists. In this perspective, we review the status of DYRK1A as a therapeutic target for β-cell proliferation and provide perspectives on technical and scientific challenges for future translational development.

Original languageEnglish
Pages (from-to)2901-2922
Number of pages22
JournalJournal of Medicinal Chemistry
Issue number6
StatePublished - 25 Mar 2021


Dive into the research topics of 'DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes'. Together they form a unique fingerprint.

Cite this